DIACHEX+DETERMINE BLOOD GLUCOSE MONITORING SYSTEM, DIACHEX-INFINITY BLOOD GLUCOSE MONITORING SYSTEM
Device Facts
| Record ID | K073492 |
|---|---|
| Device Name | DIACHEX+DETERMINE BLOOD GLUCOSE MONITORING SYSTEM, DIACHEX-INFINITY BLOOD GLUCOSE MONITORING SYSTEM |
| Applicant | Tyson Bioresearch, Inc. |
| Product Code | NBW · Clinical Chemistry |
| Decision Date | Apr 8, 2008 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 862.1345 |
| Device Class | Class 2 |
| Attributes | Pediatric |
Indications for Use
The DIACHEX* DETERMINE / DIACHEX* INFINITY Blood Glucose Monitoring System is intended for use in the quantitatively measurement of glucose (sugar) in fresh capillary whole blood from the fingertip and the alternative sites: the palm and the forearm. The DIACHEX DETERMINE / DIACHEX INFINITY Blood Glucose Test Strips are for testing outside the body (in vitro diagnostic use). The DIACHEX* DETERMINE / DIACHEX* INFINITY Blood Glucose Monitoring System is intended for use at home (over the counter [OTC]) by persons with diabetes, or in clinical setting by healthcare professionals as an aid in monitoring the effectiveness of diabetes control. It is not intended for the diagnosis of or screening for diabetes mellitus. The alternative site testing in the systems can be used only during steady-state blood glucose conditions. It is not intended for neonatal testing.
Device Story
System measures glucose in capillary whole blood (fingertip, palm, forearm) via electrochemical biosensor (glucose oxidase). User applies 0.5 uL sample to test strip; meter measures electrical current proportional to glucose concentration. DETERMINE model uses Glucode chip for strip coding; INFINITY model uses factory-programmed fixed code. Systems include meter, test strips, control solutions, and lancing device. Used at home (OTC) or in clinical settings. Data can be downloaded to PC via RS232 port. Provides quantitative glucose results to aid diabetes management. Alternative site testing restricted to steady-state conditions.
Clinical Evidence
Clinical accuracy evaluated in 112 lay users and 124 technician-performed tests across 2 clinical sites and 1 OTC site. Samples ranged 33-581 mg/dL. Fingertip, palm, and forearm testing compared against YSI-2300 reference. Results showed 97.3%-100% of samples met ISO 15197 requirements (±15mg/dL for <75mg/dL; ±20% for ≥75mg/dL). Bench testing included precision (CV% 1.65-4.78%), linearity (R² >0.999), hematocrit effect (29-59%), altitude (up to 7545 ft), and interference testing for 18 substances.
Technological Characteristics
Electrochemical biosensor using glucose oxidase. Measuring range 20-600 mg/dL. Sample volume 0.5 uL. Connectivity via RS232 for PC data download. DETERMINE model uses Glucode chip; INFINITY model uses factory-programmed fixed code. Complies with ISO 15197.
Indications for Use
Indicated for quantitative measurement of glucose in fresh capillary whole blood from fingertip, palm, or forearm. Intended for home (OTC) use by persons with diabetes or in clinical settings by healthcare professionals to monitor diabetes control. Not for diagnosis or screening of diabetes mellitus. Not for neonatal testing. Alternative site testing only during steady-state blood glucose conditions.
Regulatory Classification
Identification
A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.
Special Controls
*Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
Predicate Devices
- DIACHEX Blood Glucose Monitoring System (k062829)
Related Devices
- K072441 — EZ SCAN PLUS BLOOD GLUCOSE MONITORING SYSTEM · Tyson Bioresearch, Inc. · Mar 25, 2008
Submission Summary (Full Text)
{0}
1
# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE
A. 510(k) Number:
k073492
B. Purpose for Submission:
New Device
C. Measurand:
Whole blood glucose
D. Type of Test:
Quantitative amperometric, glucose oxidase
E. Applicant:
Tyson Bioresearch Inc.
F. Proprietary and Established Names:
DIACHEX DETERMINE Blood Glucose Monitoring System
DIACHEX INFINITY Blood Glucose Monitoring System
G. Regulatory Information:
1. Regulation section:
21 CFR § 862.1345, Glucose Test System
2. Classification:
Class II
3. Product code:
NBW - System, Test, Blood Glucose, Over the Counter
CGA - Glucose Oxidase, Glucose
4. Panel:
75 (Clinical Chemistry)
H. Intended Use:
1. Intended use(s):
See Indications for use below.
2. Indication(s) for use:
The DIACHEX DETERMINE / DIACHEX INFINITY Blood Glucose Monitoring System is intended for use in the quantitatively measurement of glucose (sugar) in fresh capillary whole blood from the fingertip and the alternative sites: the palm and the forearm. The DIACHEX DETERMINE / DIACHEX INFINITY Blood Glucose Test Strips are for testing outside the body (in vitro diagnostic use). The DIACHEX DETERMINE / DIACHEX INFINITY Blood Glucose Monitoring System is intended for use at home (over the counter [OTC]) by persons with diabetes, or in clinical setting by healthcare professionals as an aid in monitoring the effectiveness of diabetes control. It is not intended for the diagnosis of or screening for diabetes mellitus. The alternative site testing in the systems can be
{1}
used only during steady-state blood glucose conditions. It is not intended for neonatal testing.
3. Special conditions for use statement(s):
For Over-the-Counter use.
The alternative site testing in the DIACHEX DETERMINE / DIACHEX INFINITY Blood Glucose Monitoring Systems can be used only during steady-state blood glucose conditions.
Alternative site testing (AST) should ONLY be used in the following intervals:
- In a pre-meal or fasting state (more than 2 hours since the last meal)
- Two hours or more after taking insulin
- Two hours or more after exercise
It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates. For in vitro diagnostic use only, Over the Counter and professional use. The device should not be used for patients who are dehydrated, in shock, critically ill or in a hyperosmolar state.
4. Special instrument requirements:
DIACHEX DETERMINE blood glucose meter
DIACHEX INFINITY blood glucose meter
I. Device Description:
DIACHEX DETERMINE / DIACHEX INFINITY Blood Glucose monitoring systems each consist of the blood glucose meter, test strips, control solutions (3 levels of DIACHEX control solutions), and the lancing device with lancets. In addition, DIACHEX DETERMINE system kit has a Glucode chip for strip coding. The sponsor recommends that only corresponding DIACHEX test strips and control solutions specified in the manual be used with the blood glucose meters. The performance of the test strips is verified by the control solutions (cleared under k052818).
J. Substantial Equivalence Information:
1. Predicate device name(s):
DIACHEX Blood Glucose Monitoring System
2. Predicate 510(k) number(s):
k062829
3. Comparison with predicate:
Similarities
The sponsor claims that there were no changes to the main electronic component, function of the meter, and detection algorithm. Additionally, blood glucose test strips are identical to the previously cleared DIACHEX blood glucose test strips, except for the shape of the electrode.
2
{2}
3
Differences
| Item | Proposed Device | | Predicate DIACHEx (k062829) |
| --- | --- | --- | --- |
| | DIACHEx DETERMINE | DIACHEx INFINITY | |
| Blood Sample | Fingertip, Palm, and Forearm | Fingertip, Palm, and Forearm | Fingertip |
| Sample volume | 0.5 uL | 0.5 uL | 0.5 uL |
| Test time | 5 seconds | 5 seconds | 10 seconds |
| Reminder alarm | 2 user alarm settings | 4 user alarm settings | Not present |
| Hypoglycemic and hyperglycemic alarm | 2 user alarm settings | 2 user alarm settings | Not present |
| PC download option | RS232 | RS232 | Not present |
| LCD Display | Alarm, strip, code, and control solution icons | Alarm, strip, code, and control solution icons | - |
| Option of Average results | 7, 14, and 30 days | 7, 14, and 30 days | 14 days |
| Coding | Glucode chip | No coding required | Glucode chip |
| Strip eject button | Not present | One eject button | Not present |
K. Standard/Guidance Document Referenced (if applicable):
- ISO 15197: In vitro diagnostic test systems - Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus
L. Test Principle:
Glucose measurement is based on electrochemical biosensor technology using the enzyme glucose oxidase. The glucose in the sample is oxidized to produce gluconic acid. The electrical current resulting from this enzymatic reaction is measured and correlated to glucose concentration by the meter. The magnitude of the current is proportional to the concentration of glucose in the sample. The test strip is calibrated to display the equivalent of plasma glucose values to allow comparison of results with laboratory methods.
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
The sponsor evaluated within-day precision of the device using whole blood samples spiked with five different glucose concentrations, tested using three test strip lots and 10 glucose meters. All blood samples were maintained at hematocrit level of approximately 42%. Each glucose concentration level was evaluated using
{3}
10 measurements. The sponsor conducted day-to-day precision studies using three levels of glucose control solutions each with three lots of test strips and using 10 meters over ten days. Results are summarized in the tables below.
Within-day precision
| Lot No. | DIACHEX DETERMINE | | | | | DIACHEX INFINITY | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | YSI | Avg. | Bias (%) | SD | CV (%) | YSI | Avg. | Bias (%) | SD | CV (%) |
| Lot 1 | 37.1 | 38.2 | 3.0 | 1.94 | 5.08 | 39.2 | 38.4 | -2.0 | 1.98 | 5.15 |
| | 85.4 | 83.1 | -2.7 | 2.94 | 3.54 | 83.6 | 81.5 | -2.5 | 2.67 | 3.28 |
| | 125 | 118.3 | -5.4 | 4.37 | 3.69 | 132 | 130.0 | -1.6 | 3.96 | 3.05 |
| | 216 | 213.5 | -1.2 | 5.17 | 2.42 | 224 | 221.8 | -1.0 | 5.30 | 2.39 |
| | 351 | 360.8 | 2.8 | 7.64 | 2.12 | 357 | 355.3 | -0.5 | 7.76 | 2.18 |
| Lot 2 | 39.2 | 41.7 | 6.5 | 1.69 | 4.04 | 41.4 | 40.3 | -2.7 | 1.74 | 4.32 |
| | 95.2 | 91.3 | -4.1 | 2.70 | 2.96 | 85.8 | 84.7 | -1.3 | 2.89 | 3.41 |
| | 135 | 131.7 | -2.5 | 3.81 | 2.89 | 130 | 129.8 | -0.1 | 3.77 | 2.90 |
| | 220 | 216.6 | -1.5 | 5.72 | 2.64 | 219 | 218.1 | -0.4 | 5.59 | 2.56 |
| | 349 | 350.3 | 0.4 | 7.35 | 2.10 | 362 | 364 | 0.5 | 8.10 | 2.23 |
| Lot 3 | 36.9 | 38.1 | 3.1 | 1.85 | 4.87 | 40.7 | 39.8 | -2.2 | 1.94 | 4.88 |
| | 89.3 | 91.9 | 2.9 | 2.82 | 3.06 | 87.9 | 87.5 | -0.5 | 2.94 | 3.35 |
| | 130 | 125.9 | -3.2 | 4.13 | 3.28 | 126 | 124.6 | -1.2 | 4.35 | 3.49 |
| | 236 | 233.5 | -1.1 | 5.24 | 2.24 | 226 | 222.5 | -1.6 | 6.04 | 2.71 |
| | 358 | 365.9 | 2.2 | 7.7 | 2.10 | 353 | 354.5 | 0.4 | 6.68 | 1.88 |
Day-to-day precision
| Control level (mg/dL) | Statistics | DIACHEX DETERMINE | | | DIACHEX INFINITY | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| | | Lot 1 | Lot 2 | Lot 3 | Lot 1 | Lot 2 | Lot 3 |
| Level 1 | Mean | 39.0 | 38.3 | 38.5 | 37.7 | 37.6 | 37.8 |
| | SD | 1.71 | 1.83 | 1.90 | 1.80 | 1.84 | 1.66 |
| | CV% | 4.38 | 4.76 | 4.94 | 4.76 | 4.88 | 4.40 |
| Level 2 | Mean | 109.4 | 114.5 | 110.3 | 109.3 | 109.4 | 109.4 |
| | SD | 2.93 | 2.82 | 3.40 | 2.94 | 2.82 | 2.83 |
| | CV% | 2.68 | 2.46 | 3.08 | 2.69 | 2.58 | 2.59 |
| Level 3 | Mean | 405.7 | 396.3 | 403.3 | 403.1 | 400.2 | 400.7 |
| | SD | 6.45 | 6.76 | 7.38 | 6.27 | 6.74 | 6.90 |
| | CV% | 1.59 | 1.71 | 1.83 | 1.55 | 1.68 | 1.72 |
b. Linearity/assay reportable range:
The sponsor used whole blood samples from volunteers depleted of glucose and then spiked with B-D-Glucose to desired concentrations. The sponsor used 10
{4}
different levels (YSI values: $24.6\mathrm{mg / dL}$ , $46.1\mathrm{mg / dL}$ , $76.4\mathrm{mg / dL}$ , $124\mathrm{mg / dL}$ , $182\mathrm{mg / dL}$ , $234\mathrm{mg / dL}$ , $352\mathrm{mg / dL}$ , $443\mathrm{mg / dL}$ , $518\mathrm{mg / dL}$ , $572\mathrm{mg / dL}$ ) covering the glucose range of $20 - 600\mathrm{mg / dL}$ . The samples were evaluated using three lots and 10 meters from each type of glucose meter, generating 10 values per glucose level. The values generated were compared to YSI generated values. The linear regression analysis of data generated is given in the table below.
| Regression | DIACHEX DETERMINE | | | DIACHEX INFINITY | | |
| --- | --- | --- | --- | --- | --- | --- |
| | Lot 1 | Lot 2 | Lot 3 | Lot 1 | Lot 2 | Lot 3 |
| Slope | 1.02 | 1.00 | 1.02 | 1.01 | 1.00 | 1.01 |
| Intercept | -3.31 | -2.24 | -1.37 | -1.79 | -1.23 | -1.51 |
| R2 | 0.9996 | 0.9997 | 0.9997 | 0.9999 | 0.9997 | 0.9997 |
c. Traceability, Stability, Expected values (controls, calibrators, or methods): The sponsor claims that the only change made to the test strip compared to the predicate was the shape of the electrodes. Based on the ongoing studies, the sponsor demonstrated that there was $< 10\%$ bias between the values generated for five months at $40^{\circ}\mathrm{C}$ .
The control solutions supplied with the device were cleared under k052818.
There is an additional feature, the no coding feature, on the INFINITY model only, which allows a single fixed-code number to be programmed into the meters at the time of manufacturing.
d. Detection limit:
The sponsor has established the measuring range of $20 - 600\mathrm{mg / dL}$ based on the linearity studies for DIACHEX DETERMINE and DIACHEX INFINITY Blood Glucose Monitoring Systems.
e. Analytical specificity:
Following CLSI EP7 guidelines, the sponsor tested the exogenous and endogenous substances listed in the table below for interference at two glucose concentrations. For each substance, one control sample (no interferent) and four test samples with series of dilution concentrations were prepared. Each sample was measured at glucose concentrations of approximately $60 - 80\mathrm{mg / dL}$ and $200 - 285\mathrm{mg / dL}$ respectively. Results were averaged for the control samples $(n = 5)$ and for the four parallel test samples $(n = 5)$ . The mean difference between control and test samples was calculated as: Glucose Difference $(\%) = 100\%$ x [Mean (Test Sample) - Mean (Control)] / Mean (Control). Based on the interference limit of a mean glucose difference of $\pm 10\%$ of the glucose values obtained in the absence of interfering substances, the following no interference levels were established by the sponsor.
{5}
| Interferent | Physiologic/Therapeutic Test Level (mg/dL) | High Test Level (mg/dL) | No Interference Level (mg/dL) | Blood Glucose concentration (mg/dL) | |
| --- | --- | --- | --- | --- | --- |
| | | | | Low level | High Level |
| Acetaminophen | 2 | 4 | 3 | 76.3 | 265 |
| Ascorbic acid | 2 | 15 | 7.5 | 76.7 | 272 |
| Bilirubin | 1.2 | 20 | 20 | 72.9 | 277 |
| Cholesterol | 30 | 500 | 375 | 82.3 | 277 |
| Creatinine | 1.5 | 30 | 30 | 72.2 | 275 |
| EDTA | --- | 4 | 4 | 75.2 | 245 |
| Galactose | --- | 20 | 20 | 70.7 | 281 |
| Glycerol | --- | 9.21 | 9.21 | 73.4 | 265 |
| Heparin | --- | 60 | 60 | 69.9 | 270 |
| Ibuprofen | 4.2 | 40 | 40 | 68.5 | 255 |
| L-Dopa | 0.3 | 2 | 1 | 68.9 | 265 |
| Maltose | --- | 40 | 40 | 74.4 | 266 |
| Salicylate | 30 | 125 | 125 | 71.1 | 255 |
| Sodium Fluoride | --- | 500 | 500 | 65.1 | 248 |
| Tetracycline | 0.4 | 4 | 4 | 62.1 | 265 |
| Tolazamide | 2.5 | 5 | 3.75 | 72.6 | 265 |
| Tolbutamide | 10 | 100 | 100 | 66.6 | 244 |
| Triglyceride | 190 | 2000 | 2000 | 73.0 | 251 |
| Uric acid | 7.7 | 20 | 15 | 67.7 | 266 |
The sponsor evaluated the effect of hematocrit levels between 29 – 59% on whole blood samples spiked with 11 hematocrit levels at 4 levels of glucose distributed within the measuring range (45 - 372 mg/dL) of the device. The mean values of the 6 replicated measurements generated were compared with the glucose values from YSI 2300 analyzer. Based on the regression analysis, the results generated by the device are comparable to the values of YSI-2300 instrument at hematocrit levels between 35-55%.
An altitude study was performed with whole blood samples from 20 volunteers (glucose range: 68-157 mg/dL) at elevations of 164 feet, 5084 feet, 7545 feet, and 10168 feet. Altitude differences within individuals were within ±10mg/dL deviation for glucose concentration of <75 mg/dL and ±15% deviation for glucose concentration of ≥75 mg/dL. They also showed acceptable correlation (R²: 0.9803-0.9990) based on the linear regression analysis.
f. Assay cut-off:
Not Applicable.
{6}
# 2. Comparison studies:
# a. Method comparison with predicate device:
The sponsor conducted accuracy studies to demonstrate that the DIACHEX DETERMINE / DIACHEX INFINITY Blood Glucose Monitoring Systems are equivalent to a standard reference method (YSI-2300). Samples from 118 volunteers that included 13 contrived samples covering the lower (7 samples: 25.4-49 mg/dL glucose) and upper (6 samples: 460-571 mg/dL glucose) ends of the glucose measuring range were evaluated. The hematocrit levels of the 118 samples ranged from 34-51%. All participants claimed to be in glucose steady state. Percent distribution of the samples corresponding to the glucose concentration ranged as follows: $<50 \, \text{mg/dL} - 5.9\%$ ; 50-80 mg/dL - 13.6%; 80-120 mg/dL - 17.8%; 120-200 mg/dL - 30.5%; 200-300 mg/dL - 15.3%; 300-400 mg/dL - 10.2%; and $>400 \, \text{mg/dL} - 6.8\%$ . This test was conducted by a laboratory technician. Based on data analysis, the device met the minimum system accuracy requirement established according to the ISO 15197 guidelines, which is that $95\%$ of the individual differences are within $\pm15 \, \text{mg/dL}$ when glucose concentration is less than $75 \, \text{mg/dL}$ , and within $\pm20\%$ when glucose concentration $\geq75 \, \text{mg/dL}$ . Results of the linear regression analysis are summarized in the table below.
| Technician evaluation Fingertip (N=118) | Predicate DIACHEX | DIACHEX DETERMINE | DIACHEX INFINITY |
| --- | --- | --- | --- |
| slope | 0.98 | 0.98 | 0.98 |
| y=intercept | 0.62 | -0.32 | 1.31 |
| R square | 0.9843 | 0.9867 | 0.9879 |
Using DIACHEX DETERMINE meter, the sponsor conducted a second study to demonstrate the accuracy of lay user testing for fingertip, palm and forearm. This study included 112 lay users and 12 contrived samples covering the extreme ends of the range (i.e. $33 - 48\mathrm{mg / dL}$ and $462 - 581\mathrm{mg / dL}$ ). All participants claimed to be in glucose steady state. Lay users were first requested to test the blood glucose using the fingertip, the palm, and the forearm, followed by trained technicians performing the fingertip test and YSI laboratory test. The values obtained were compared with the values generated using YSI. Based on data analysis, the device met the minimum system accuracy requirement established according to the ISO 15197 guidelines, which is that $95\%$ of the individual differences are within $\pm 15\mathrm{mg / dL}$ when glucose concentration is less than $75\mathrm{mg / dL}$ and within $\pm 20\%$ when glucose concentration is $\geq 75\mathrm{mg / dL}$ . Linear regression analysis of the lay user and technician values compared with YSI values are summarized below.
{7}
| Fingertip | Lay User vs. YSI (N=112) | Technician vs. YSI (N=124) | Lay User vs. Technician (N=112) |
| --- | --- | --- | --- |
| slope | 0.98 | 0.97 | 1.00 |
| y=intercept | -0.52 | 1.31 | -0.62 |
| R square | 0.9789 | 0.9872 | 0.9900 |
The sponsor's alternate site testing (AST) is limited to the palm and the forearm. Using the same volunteers described above, with hematocrit levels ranging from $33 - 54\%$ , the linear regression analysis conducted is summarized in the following table for DIACHEX DETERMINE.
| Comparison | N | Slope and Y-intercept | R2 |
| --- | --- | --- | --- |
| Finger vs. YSI | 112 | y= 0.98x-0.52 | 0.9789 |
| Palm vs. YSI | 111 | y=0.96x-1.77 | 0.9796 |
| Palm vs. fingertip | 111 | y=0.97x+3.12 | 0.9861 |
| Forearm vs YSI | 111 | y=0.95x+2.34 | 0.9745 |
| Forearm vs. fingertip | 111 | y=0.96x+3.54 | 0.9825 |
Based on data analysis, the device met the minimum system accuracy requirement established according to the ISO 15197 guidelines as follows:
Difference distribution for glucose concentrations $< 75\mathrm{mg / dL}$
| Within ± 5 mg/dL | Within ± 10 mg/dL | Within ± 15 mg/dL |
| --- | --- | --- |
| 17/20 (85%) | 19/20 (95%) | 20/20 (100%) |
Difference distribution for glucose concentrations $\geq 75\mathrm{mg / DL}$
| Within ± 10% | Within ± 15% | Within ± 20% |
| --- | --- | --- |
| 110/116 (95%) | 114/116 (98%) | 116/116 (100%) |
b. Matrix comparison:
Not applicable
3. Clinical studies:
a. Clinical Sensitivity:
Not Applicable.
b. Clinical specificity:
Not Applicable.
c. Other clinical supportive data (when a. and b. are not applicable):
Not Applicable.
4. Clinical cut-off:
Not Applicable
{8}
9
5. Expected values/Reference range:
Based on the published literature, the sponsor included the following Expected Values for normal glucose levels in their strip labeling:
| Status | Plasma glucose range for people without diabetes (mg/dL) |
| --- | --- |
| Before meals | 70-110 |
| 2 hours after meals | <120 |
Source: American Diabetic Association Clinical Practice Recommendations 2003
N. Instrument Name:
DIACHEX DETERMINE and DIACHEX INFINITY Blood Glucose Monitoring Systems
O. System Descriptions:
1. Modes of Operation:
Each test strip is single use and must be replaced with a new strip for additional readings.
2. Software:
FDA reviewed applicant’s Hazard Analysis and software development processes for this line of product types in k052818. Additionally, in this submission, the sponsor provided data to support the accuracy of PC downloaded feature that allows the user to download glucose meter readings to a personal computer. Only the memory information within DETERMINE and INFINITY glucose meters can be downloaded to PC through RS-232 port and can be cleared by software. The sponsor also provided all Over The Shelf Software (OTSS) components and related design validation verification and testing activities.
3. Specimen Identification:
There is no sample identification function with this device. Samples are applied directly to the test strip as they are collected.
4. Specimen Sampling and Handling:
This device is intended to be used with capillary whole blood from the finger, the palm, and the forearm only. Since the whole blood sample is applied directly to the test strip, there are no special handling or storage issues.
5. Calibration:
For DIACHEX DETERMINE, a code strip is provided with each batch of test strips to calibrate the meter for that batch. No further calibrations are required of the user. For DIACHEX INFINITY, a single calibration code is programmed into the meters at the time of manufacturing.
6. Quality Control:
Glucose control solutions at three different concentrations to be run with this device are available for use but not supplied with the device. An acceptable range for each control level is printed on the test strip vial label. The user is referred to
{9}
the troubleshooting section of the owner's manual if control results fall outside these ranges. There are three DIACHEX Control Solutions (Low, Normal, and High) for each of the three meters that are available for the user to choose from. The sponsor recommends the use of at least two controls solutions, normal with the user's choice of either high or low control solution to check the accuracy of the system.
P. Other Supportive Instrument Performance Characteristics Data Not Covered In The "Performance Characteristics" Section above:
Not applicable
Q. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
R. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
10
